The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease

Glen E. Coole, Pascal Goldschmidt-Clermont

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.

Original languageEnglish
Pages (from-to)815-826
Number of pages12
JournalExpert Opinion on Drug Safety
Volume5
Issue number6
DOIs
StatePublished - Nov 1 2006

Fingerprint

clopidogrel
Aspirin
Coronary Disease
Standard of Care
Safety
Hemorrhage
Drug-Eluting Stents
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Stents
Coronary Artery Disease
Therapeutics
Metals
Clinical Trials
Wounds and Injuries

Keywords

  • Aspirin
  • Atherothrombosis
  • Blood platelet
  • Clopidogrel
  • Coronary artery disease

ASJC Scopus subject areas

  • Pharmacology

Cite this

The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. / Coole, Glen E.; Goldschmidt-Clermont, Pascal.

In: Expert Opinion on Drug Safety, Vol. 5, No. 6, 01.11.2006, p. 815-826.

Research output: Contribution to journalArticle

@article{1bdcee6625c747769377a5ee2cd97800,
title = "The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease",
abstract = "The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.",
keywords = "Aspirin, Atherothrombosis, Blood platelet, Clopidogrel, Coronary artery disease",
author = "Coole, {Glen E.} and Pascal Goldschmidt-Clermont",
year = "2006",
month = "11",
day = "1",
doi = "10.1517/14740338.5.6.815",
language = "English",
volume = "5",
pages = "815--826",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease

AU - Coole, Glen E.

AU - Goldschmidt-Clermont, Pascal

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.

AB - The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.

KW - Aspirin

KW - Atherothrombosis

KW - Blood platelet

KW - Clopidogrel

KW - Coronary artery disease

UR - http://www.scopus.com/inward/record.url?scp=33750555770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750555770&partnerID=8YFLogxK

U2 - 10.1517/14740338.5.6.815

DO - 10.1517/14740338.5.6.815

M3 - Article

VL - 5

SP - 815

EP - 826

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -